Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $6.9272 (-0.51%) ($6.7900 - $7.1400) on Sat. May. 11, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.44% (three month average) | RSI | 30 | Latest Price | $6.9272(-0.51%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -0.4% a day on average for past five trading days. | Weekly Trend | HTBX declines -5.6% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) (0%) (0%) (0%) (0%) (0%) | Factors Impacting HTBX price | HTBX will decline at least -2.22% in a week (0% probabilities). (0%) (0%) (0%) (0%) (0%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.22% (StdDev 4.44%) | Hourly BBV | 0 () | Intraday Trend | -0.5% | | | |
|
1 - 5 Day Possible Target | $-3.38(-148.79%) | Resistance Level | $7.56 | 5 Day Moving Average | $7.06(-1.88%) | 10 Day Moving Average | $7.2(-3.79%) | 20 Day Moving Average | $7.56(-8.37%) | To recent high | -42.8% | To recent low | 0% | Market Cap | $N/A | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |